VisEn debuts IntegriSense

By staff writers

August 19, 2008 -- Optical imaging developer VisEn Medical has launched its IntegriSense fluorescence molecular imaging agent.

The agent will allow researches to image and assess the role of integrin alpha v beta 3 in disease progression and therapeutic response in vivo, according to VisEn of Woburn, MA. The agent is the first product to be developed from a research collaboration between VisEn and pharmaceutical firm Merck of Whitehouse Station, NJ, that was announced in 2007.

VisEn nets $3.5M in financing, July 22, 2008

VisEn secures financing, October 26, 2007

VisEn brings molecular imaging probe to market, June 7, 2007

VisEn, Merck to develop molecular imaging agents, March 6, 2007

VisEn, Olympus expand distribution relationship, December 11, 2006

Copyright © 2008


To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking